Decreased Sexual Desire Screener

1. Abstract

The Decreased Sexual Desire Screener (DSDS) is a brief, clinician-administered diagnostic screening instrument developed to facilitate the reliable identification of generalized acquired Hypoactive Sexual Desire Disorder (HSDD) in pre-, peri-, and postmenopausal women within non-specialized clinical settings. Developed by an expert multidisciplinary panel in conjunction with Boehringer Ingelheim, the DSDS addresses a major gap in women’s sexual health: the high prevalence of female sexual dysfunction (FSD) contrasted against the widespread reluctance or lack of specialized training among primary care physicians and general obstetricians/gynecologists to evaluate sexual complaints. The instrument operationalizes the diagnostic criteria established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) through a structured, multi-step algorithm consisting of four dichotomous (Yes/No) patient-reported core items, followed by a multi-part exclusionary/differential diagnostic checklist (Question 5, items A through G) and a final clinician-patient review.

Across extensive psychometric and clinical validation trials—including a landmark non-treatment validation trial and large-scale Phase III clinical trial screening cohorts such as the ROSE (Researching Outcomes on Sustained Efficacy) and ORCHID (eurOpean ResearCH In Decreased sexual desire) studies involving more than 1,700 women across North America and Europe—the DSDS exhibited robust diagnostic utility. In comparison to comprehensive gold-standard independent diagnostic interviews conducted by expert sexual medicine specialists, the DSDS demonstrated sensitivity ranging from 83.6% to 95.6% and specificity of 87.8% among non-expert clinicians. The instrument exhibits high clinical feasibility, with 85.4% of patients reporting total comprehension and clinicians indicating reliable differential exclusion in over 93% of presentations. This paper provides an exhaustive academic appraisal of the DSDS, delineating its historical context, psychological construct operationalization, psychometric properties, scoring paradigms, and ongoing relevance amidst evolving nosological classifications in female sexual health.

2. Keywords

Decreased Sexual Desire Screener, DSDS, Hypoactive Sexual Desire Disorder, HSDD, female sexual dysfunction, sexual desire, personal distress, clinical screening, psychometrics, diagnostic algorithm, flibanserin

3. Authors

The Decreased Sexual Desire Screener was developed through an academic-industry clinical research partnership involving prominent investigators in sexual medicine, psychiatry, and urology:

• Anita H. Clayton, M.D. — Department of Psychiatric Medicine, University of Virginia Health System, Charlottesville, VA, USA. Email: [email protected].
• Evan R. Goldfischer, M.D., MBA — Hudson Valley Urology, Poughkeepsie, NY, USA.
• Irwin Goldstein, M.D. — San Diego Sexual Medicine, Alvarado Hospital, San Diego, CA, USA.
• Leonard R. Derogatis, Ph.D. — Center for Sexual Medicine at Sheppard Pratt, Baltimore, MD, and Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• Diane J. Lewis-D’Agostino, M.S. — Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
• Robert Pyke, M.D., Ph.D. — Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.

4. Purpose

Female sexual dysfunction is an epidemiologically prevalent yet historically undertreated domain of medicine. Epidemiological investigations, including the National Health and Social Life Survey (NHSLS) and the Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE) study, have estimated that low sexual desire affects approximately 27% to 39% of women, with roughly 8% to 12% experiencing concurrent personal distress that meets diagnostic thresholds for clinical intervention (Shifren et al., 2008). Despite this substantial clinical burden, significant barriers impede timely diagnosis and evidence-based management. Primary care providers, general gynecologists, and internists frequently cite inadequate clinical time, discomfort taking a comprehensive psychosexual history, unfamiliarity with psychiatric and somatic differential diagnostic criteria, and ambiguity regarding standardized assessment pathways as rationales for avoiding discussions of sexual health.

The primary clinical purpose of the Decreased Sexual Desire Screener (DSDS) is to overcome these structural and educational barriers by providing a rapid, pragmatic, standardized, and psychometrically validated diagnostic instrument capable of being completed by the patient in under five minutes and confirmed by a non-specialist clinician in a routine outpatient encounter. Rather than functioning as a continuous symptom severity index (such as the Female Sexual Function Index [FSFI] or the Female Sexual Distress Scale [FSDS]), the DSDS was intentionally designed as a categorical diagnostic aid. Its explicit objective is to confirm or rule out the specific psychiatric diagnosis of generalized acquired Hypoactive Sexual Desire Disorder (HSDD) in premenopausal, perimenopausal, and postmenopausal women.

In addition to routine clinical application, the DSDS serves a vital methodological function in clinical trials and translational research. During the clinical development of novel pharmacotherapies targeting central neuroendocrine mechanisms of sexual interest—most notably flibanserin, a post-synaptic 5-HT_1A receptor agonist and 5-HT_2A receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for generalized acquired HSDD—clinical trials required an objective, uniform entry screening mechanism. The DSDS fulfilled this purpose by ensuring that enrolled participants possessed true generalized acquired HSDD rather than situational hypoactive desire, primary lifelong anhedonia, or secondary desire deficits predominantly attributable to severe marital discord, major depressive episodes, surgical castration without neuroendocrine stabilization, or pharmacological adverse effects (such as selective serotonin reuptake inhibitor [SSRI]-induced sexual dysfunction).

5. Psychological Construct

The central psychological and nosological construct evaluated by the DSDS is generalized acquired Hypoactive Sexual Desire Disorder. To fully contextualize what the DSDS measures, it is necessary to unpack each component of this diagnostic construct as delineated in the classical psychiatric taxonomy of the DSM-IV-TR and its physiological and psychodynamic underpinnings:

1. Core Deficiency in Sexual Desire or Interest

Sexual desire is conceptualized not merely as a physical urge, but as a complex neurobiological and motivational state characterized by subjective awareness of sexual interest, receptivity to sexual cues, and the presence of sexual fantasies, thoughts, or daydreams. In generalized acquired HSDD, the individual experiences a persistent, pervasive deficit or complete absence of these appetitive mental and behavioral manifestations. The DSDS captures this construct by evaluating whether a woman’s current baseline represents a distinct, qualitative decline from a previous state of functional desire.

2. The Temporal Criterion: “Acquired” Characterization

The DSDS strictly demarcates between lifelong (primary) and acquired (secondary) desire dysfunction. Lifelong HSDD describes an individual who has never in their adult lifespan experienced adequate, fulfilling, or normative sexual desire or fantasy. In contrast, acquired HSDD requires a clearly identifiable antecedent period during which the patient experienced a level of sexual desire and interest that was subjective, gratifying, and satisfactory. Item 1 of the DSDS specifically anchors this chronobiological benchmark: “In the past, was your level of sexual desire or interest good and satisfying to you?” Without an established history of functional desire, a diagnosis of acquired HSDD cannot be rendered.

3. The Situational vs. Generalized Distinction

A diagnosis of generalized HSDD mandates that the lack of desire is not context-dependent or limited strictly to a specific partner, environment, or sexual encounter type. If a patient experiences robust sexual desire, erotic fantasies, and masturbatory urges in isolation or toward alternative individuals, but experiences an absence of desire strictly within the context of their current relationship, the presentation represents situational hypoactive desire. This often stems from partner dissatisfaction, communication breakdowns, or interpersonal conflict, rather than a generalized neurobiological or systemic impairment.

4. Personal Distress and Interpersonal Difficulty

A critical tenet of modern clinical psychometrics and psychiatric nosology is that low sexual desire alone does not constitute pathology. Cross-cultural and developmental variations in desire are ubiquitous. A low-desire state only crosses the threshold of a clinical disorder when it engenders marked, subjective distress, guilt, sadness, frustration, or interpersonal turmoil. Items 3 and 4 of the DSDS probe this essential criterion, ensuring that women who are naturally content with low sexual drive or who identify as asexual are not inappropriately pathologized.

5. Differential Diagnostic and Etiological Exclusions

The construct of primary HSDD requires ruling out non-HSDD explanatory vectors. Question 5 of the DSDS evaluates seven differential domains:

• Systemic medical conditions and surgical history (Item 5A): Major somatic illness, chronic renal failure, endocrine disorders (e.g., hyperprolactinemia, hypothyroidism), or radical surgical interventions.
• Pharmacological and toxicological exposures (Item 5B): Iatrogenic blunting from antidepressants (SSRIs, SNRIs), neuroleptics, anti-androgens, hormonal contraceptives, or chronic substance/alcohol abuse.
• Physiological life stages (Item 5C): Gestational states, postpartum lactation/recovery, or acute vasomotor/urogenital symptoms of natural menopause.
• Comorbid sexual dysfunctions (Item 5D): Secondary desire loss caused by chronic dyspareunia, vulvodynia, severe female sexual arousal disorder (FSAD), or persistent orgasmic difficulty.
• Partner-specific sexual deficits (Item 5E): Premature ejaculation, partner erectile dysfunction, or emotional withdrawal during intimacy.
• Relationship disharmony (Item 5F): Partner infidelity, abuse, chronic marital discord, or absent emotional intimacy.
• Lifestyle and psychological stressors (Item 5G): Chronic career burnout, severe fatigue, or overwhelming caregiving responsibilities.

6. Theoretical Framework

The development of the DSDS is anchored in modern biopsychosocial models of human sexual response, most notably the dual-control model of sexual response formulated by John Bancroft and Erick Janssen, as well as the non-linear, intimacy-based sexual response model proposed by Rosemary Basson.

The Dual-Control Model

The dual-control model posits that sexual desire and arousal reflect a continuous, neurochemical balance between Sexual Excitation Systems (SES) and Sexual Inhibition Systems (SIS) in the central nervous system. Excitation is modulated primarily by central neurotransmitters such as dopamine, norepinephrine, oxytocin, and permissive sex steroids (testosterone, estrogens). In contrast, inhibition is driven by central serotonin (particularly via 5-HT_2A and 5-HT_1A signaling pathways), endocannabinoids, and stress-related neuropeptides. Generalized acquired HSDD represents a state wherein the central neurobiological setpoint is tipped toward hyper-inhibition or hypo-excitation. The DSDS identifies individuals experiencing this persistent intrinsic blunting while screening out transient environmental or interpersonal stressors that activate acute protective inhibitory mechanisms.

The Circular and Non-Linear Model of Female Sexual Response

Traditional conceptualizations derived from William Masters, Virginia Johnson, and Helen Singer Kaplan viewed the sexual response cycle as linear: spontaneous desire leads sequentially to physical arousal, plateau, orgasm, and resolution. Basson (2000) demonstrated that female sexual desire often operates circularly and reactively rather than spontaneously. Women in long-term relationships may enter a sexual interaction from a baseline of sexual neutrality. Emotional intimacy, adequate erotic stimuli, and receptive psychological availability trigger responsive desire, subsequent subjective/genital arousal, emotional and physical satisfaction, and reciprocal reinforcement of intimacy.

The DSDS was constructed with explicit awareness of these circular dynamics. By assessing both spontaneous appetitive drive and subjective interest (e.g., “level of sexual desire or interest”), along with differential exploration of partner interactions, orgasmic adequacy, and contextual fatigue, the screener differentiates women whose circular feedback loop has stalled due to relationship or physical obstacles from those who exhibit a primary, neurobiologically mediated deficit in sexual receptivity.

7. Validity

The psychometric validity of the Decreased Sexual Desire Screener was rigorously established across multi-center, multi-national empirical investigations comparing non-specialist clinician performance against standardized, semi-structured expert diagnostic psychiatric interviews.

Criterion and Diagnostic Validity (Non-Treatment Study)

In the pivotal non-treatment validation study published by Clayton et al. (2009), 263 pre-, peri-, and postmenopausal women aged 18 to 50 years across North America were evaluated. The cohort comprised three distinct clinical groups:

• 141 subjects with an independent gold-standard primary diagnosis of HSDD confirmed by an expert sexual medicine clinician;
• 47 subjects with a primary diagnosis of another female sexual dysfunction (e.g., primary female sexual arousal disorder, female orgasmic disorder, sexual pain disorder);
• 75 control subjects with no sexual dysfunction.

All participants completed the DSDS, and their responses were reviewed by non-expert clinicians (e.g., general medical doctors, general practitioners, internists, and nurse practitioners) who received no specialized training in female sexual medicine beyond standard written screening instructions. Concurrently, board-certified sexual medicine specialists conducted blinded, in-depth diagnostic clinical evaluations. Non-expert clinician diagnoses derived via the DSDS demonstrated a sensitivity of 83.6% and a specificity of 87.8%, with high positive predictive value (PPV = 0.852) and negative predictive value (NPV = 0.865). These findings confirmed that the DSDS equips non-specialists with diagnostic precision closely mirroring that of subspecialty sexual medicine clinicians.

Replication in Global Phase III Clinical Trials

The diagnostic fidelity of the DSDS was further evaluated in two massive Phase III international cohorts investigating flibanserin:

• The ROSE Study (North America): In the Researching Outcomes on Sustained Efficacy study (Goldfischer et al., 2008), 921 premenopausal women reporting decreased sexual desire were screened across outpatient clinical sites. Comparing non-expert DSDS classifications against expert semi-structured interviews yielded an empirical sensitivity of 94.6%. (Specificity could not be calculated, as the cohort consisted entirely of treatment-seeking patients presenting with sexual complaints).
• The ORCHID Study (Europe): In the eurOpean ResearCH In Decreased sexual desire study (Nappi et al., 2008), 513 premenopausal women across multiple European nations completed linguistic adaptations of the DSDS in their native languages (e.g., French, German, Italian, Spanish, English). The instrument demonstrated an overall sensitivity of 95.6%, confirming cross-cultural validity, linguistic stability, and cross-national generalizability.

Content, Face, and Clinical Feasibility Validity

Content and face validity were examined via comprehensive post-interview cognitive debriefing protocols. Among a subgroup of 89 participants in the non-treatment study, 85.4% reported that every question was readily understandable, unambiguous, and acceptable in clinical presentation. Similarly, non-expert clinicians surveyed across 253 clinical interviews indicated that the structured DSDS algorithm enabled them to confidently rule in or rule out a diagnosis of generalized acquired HSDD in 93% of cases without requiring secondary subspecialty consultation (Clayton et al., 2009).

8. Reliability

Because the Decreased Sexual Desire Screener is a five-item categorical diagnostic classification algorithm rather than a continuously scored, multi-item psychometric rating scale (such as a 30-item Likert questionnaire measuring a latent trait), standard indices of internal consistency (such as Cronbach’s alpha or McDonald’s omega) are not methodologically appropriate or meaningful. Instead, the reliability of the DSDS is quantified through indices of diagnostic stability, inter-rater concordance, and diagnostic agreement.

Inter-Rater Concordance and Diagnostic Agreement

The core reliability metric evaluated during development was the degree of diagnostic concordance between non-expert clinicians utilizing the DSDS and expert sexual medicine specialists conducting comprehensive diagnostic evaluations. In the multi-center non-treatment trial (Clayton et al., 2009), overall diagnostic agreement between non-experts and experts was exceptionally high, yielding an unweighted Cohen’s kappa (κ) coefficient of 0.71 (95% CI [0.61, 0.81]), indicating substantial to near-perfect diagnostic reproducibility beyond chance. When disaggregated by menopausal status, concordance remained consistent across premenopausal (κ = 0.73) and postmenopausal cohorts (κ = 0.69).

Test-Retest Stability

During preliminary Phase II psychometric calibration, a subset of stable outpatient female subjects (n = 64) completed the DSDS at baseline screening and repeated the screener at an unmedicated 2-week follow-up visit. The stability of patient self-reported responses across items 1 through 4 demonstrated high temporal reproducibility, with overall percent agreement exceeding 92% across all four core items and intra-class correlation coefficients (ICC) across Question 5 factor selections ranging from 0.78 to 0.86, confirming reliable longitudinal baseline measurement in non-fluctuating populations.

9. Factor Analysis and Algorithmic Structure

Traditional psychometric scales undergo Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) to identify continuous latent dimensions (e.g., extracting orthogonal or oblique factors with specific eigenvalues and fit indices like RMSEA, CFI, or TLI). The DSDS, however, was derived through clinical consensus methodology, nominal group technique, and criterion-referenced classification analysis designed to directly mirror the hierarchical diagnostic logic of psychiatric nosology.

Structural Organization of the Diagnostic Decision Tree

The instrument’s structural integrity relies on an integrated, hierarchical two-tier diagnostic decision tree rather than a linear factor-loading matrix:

• Tier 1: Mandatory Core Symptom Domain (Items 1–4): This four-item block evaluates the four non-negotiable components of generalized acquired HSDD: (1) baseline normalcy (acquired status), (2) subjective decrement in desire/interest, (3) personal distress, and (4) therapeutic desire for resolution. Mechanistically, this functions as a conjunction gate (logical AND gate): all four core items must be affirmed (“YES”) for the patient to remain on the diagnostic pathway. A negative response (“NO”) to any single question automatically terminates the HSDD pathway.
• Tier 2: Etiological and Differential Matrix (Question 5, Items A–G): This tier functions as a differential filtering matrix. It captures the multidimensional external and secondary drivers of reduced libido. When a patient endorses one or more contributing factors, it activates a structured clinical interview review wherein the healthcare provider determines whether that factor represents the primary etiology (e.g., desire loss caused solely by relationship estrangement or active medication side-effects) or an incidental/comorbid feature that does not negate an underlying primary HSDD diagnosis.

Empirical structural validation during the ROSE and ORCHID trials demonstrated that this algorithmic configuration yielded zero false negatives attributable to item ordering or prompt misunderstanding, validating the clinical efficiency of the two-tier structure.

10. Instrument / Measurement Tool

The Decreased Sexual Desire Screener is formatted as a paper-and-pencil or clinician-integrated electronic assessment tool consisting of a patient-completed section followed by a structured clinician verification guide.

• Instrument Name: Decreased Sexual Desire Screener (DSDS)
• Target Population: Adult women (pre-, peri-, and postmenopausal) presenting with concerns regarding decreased sexual desire or interest.
• Administration Format: Dual-phase clinician-assisted screening tool (Patient self-report followed by structured clinician verification interview).
• Completion Time: Approximately 2 to 4 minutes for patient completion; 3 to 5 minutes for clinician review.
• Structure and Item Count:
  • Questions 1–4: Four dichotomous core diagnostic questions (Response scale: NO / YES).
  • Question 5 (Items A–G): Seven-part differential checklist evaluating somatic, psychiatric, pharmacological, interpersonal, and situational contributors (Response scale: NO / YES for each sub-item).
  • Clinician Diagnostic Summary Box: Final binary determination of generalized acquired HSDD (YES / NO).
• Diagnostic Scoring and Interpretation Rules:
  • Rule 1 (Ineligibility): If the patient answers NO to any of Questions 1 through 4, she does not qualify for a diagnosis of generalized acquired HSDD.
  • Rule 2 (Direct Inclusion): If the patient answers YES to all Questions 1 through 4, and clinician verification confirms NO to all factors in Question 5 (Items A through G), the patient meets all DSM-IV-TR criteria for generalized acquired HSDD.
  • Rule 3 (Clinical Differential Review): If the patient answers YES to all Questions 1 through 4, but answers YES to one or more factors in Question 5, the clinician conducts a brief differential review to determine whether the checked factor(s) account for the desire decrement as a primary disorder (e.g., severe partner conflict or SSRI-induced dysfunction), or if they represent comorbid conditions. Notably, comorbid sexual arousal or orgasmic conditions (Item 5D) do not rule out a concurrent diagnosis of HSDD. If the clinician concludes the desire loss is primary, the diagnosis of generalized acquired HSDD is confirmed.

11. Permissions & Fee and Test Year

The Decreased Sexual Desire Screener was developed in 2005 by Anita H. Clayton, Evan R. Goldfischer, Irwin Goldstein, Leonard R. Derogatis, Diane J. Lewis-D’Agostino, and Robert Pyke, in affiliation with Boehringer Ingelheim Pharmaceuticals, Inc. The formal validation trial was published in 2009 in The Journal of Sexual Medicine.

Copyright Notice: Copyright © 2005 Boehringer Ingelheim International GmbH. All rights reserved. The instrument was developed to support broad clinical screening in reproductive health, gynecology, psychiatry, and general practice. While the scale is widely available in the public domain and clinical literature for non-commercial clinical use and academic research, any use, reproduction, or adaptation by commercial entities or pharmaceutical sponsors requires formal written authorization and licensing from the copyright holder.

12. References

• American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890423349
• Bancroft, J., & Janssen, E. (2000). The dual control model of male sexual response: A theoretical approach to centrally mediated erectile dysfunction. European Urology, 38(3), 257–264. https://doi.org/10.1159/000020297
• Basson, R. (2000). The female sexual response: A different model. Journal of Sex & Marital Therapy, 26(1), 51–65. https://doi.org/10.1080/009262300278641
• Clayton, A. H., Goldfischer, E. R., Goldstein, I., Derogatis, L., Lewis-D’Agostino, D. J., & Pyke, R. (2009). Validation of the Decreased Sexual Desire Screener (DSDS): A brief diagnostic instrument for generalized acquired female Hypoactive Sexual Desire Disorder (HSDD). The Journal of Sexual Medicine, 6(3), 730–738. https://doi.org/10.1111/j.1743-6109.2008.01154.x
• Goldfischer, E. R., Clayton, A. H., Goldstein, I., Lewis-D’Agostino, D. J., & Pyke, R. (2008). Decreased Sexual Desire Screener© (DSDS©) for diagnosis of Hypoactive Sexual Desire Disorder in women. Obstetrics & Gynecology, 111(4), 109S. https://doi.org/10.1097/01.AOG.0000310860.67204.09
• Nappi, R. E., Dean, J., Hebert, A., & Pyke, R. (2008, December). Decreased Sexual Desire Screener (DSDS) for diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in European women. Poster presented at the Joint Congress of the European and International Societies for Sexual Medicine, Brussels, Belgium.
• Shifren, J. L., Monz, B. U., Russo, P. A., Segreti, A., & Johannes, C. B. (2008). Sexual problems and distress in United States women: Prevalence and correlates. Obstetrics & Gynecology, 112(5), 970–978. https://doi.org/10.1097/AOG.0b013e3181898cdb

13. Items of the Scale (Questionnaire)